Drug Profile
MEDI 500
Alternative Names: Anti-TCR-alphabeta monoclonal antibody T10B9; G 022; T-10B9; T10B9 monoclonal antibody; T10B9.1A31; T12A10Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator University of Kentucky Chandler Medical Center
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; T-cell receptor antigen alpha-beta antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Graft-versus-host disease; Heart transplant rejection; Liver transplant rejection; Renal transplant rejection
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 12 Mar 2004 It appears that BioTransplant has ceased operations
- 28 Nov 2003 BioTransplant expects to file with the Bankruptcy Court in the coming weeks